Literature DB >> 18095027

Patterns of esophageal acid exposure after laparoscopic Heller's myotomy and Dor's fundoplication for esophageal achalasia.

John Tsiaoussis1, George Pechlivanides, Nikolaos Gouvas, Elias Athanasakis, Nikolaos Zervakis, Apostolos Manitides, Evaghelos Xynos.   

Abstract

BACKGROUND: Heller's myotomy for esophageal achalasia is associated with less esophageal acid gastroesophageal reflux when combined a Dor's fundoplication. The Aim of the study was to assess the incidence of postoperative esophageal acid exposure after laparoscopic Heller's myotomy and Dor's fundoplication (HM-DF).
METHODS: Seventy six patients (37 males) with esophageal achalasia were prospectively followed-up by clinical interview and laboratory tests before and after laparoscopic HM-DF. A symptom score was used for clinical assessment. Laboratory assessment included esophageal standard manometry, esophagogram and esophageal pH 24-hour monitoring before and 1- and 5-years after surgery.
RESULTS: Symptom score improved at 1-year after surgery (P < 0.001). Heartburn was only reported by 5 patients, dysphagia or/and regurgitation by 28 and substernal pain by 12. 91% of patients had satisfactory functional results. Pathological esophageal exposure to acid was seen in 21% of the cases. Pathological acid events showed the features of pseudoreflux in 66%t and those of true GER in 34%. Pathologically increased esophageal exposure to acid was more commonly detected in patients with a pseudodiverticulum (P = 0.001) and was related to the diameter of distal esophagus and symptom score (P < 0.001). There was no reduction in esophageal acid exposure after treatment with proton pump inhibitors in 16 patients. Neither the symptom score nor esophageal acid exposure at esophageal pH monitoring changed significantly at the 5-year follow-up in 35 patients. Esophageal configuration remained unchanged.
CONCLUSIONS: Increased esophageal exposure to acid after laparoscopic HM-DF for esophageal achalasia i) is detected in 21% of patients, and is rather the result of food stagnation than of true GER, ii) is more commonly seen in cases with pseudodiverticulum, iii) is related to the diameter of distal esophagus, iv) does not respond to antisecretory treatment and v) does not deteriorate by time.

Entities:  

Mesh:

Year:  2007        PMID: 18095027     DOI: 10.1007/s00464-007-9681-2

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  25 in total

Review 1.  Surgery for achalasia: 1998.

Authors:  Y Shiino; C J Filipi; Z T Awad; T Tomonaga; R E Marsh
Journal:  J Gastrointest Surg       Date:  1999 Sep-Oct       Impact factor: 3.452

Review 2.  An antireflux procedure is critical to the long-term outcome of esophageal myotomy for achalasia.

Authors:  J H Peters
Journal:  J Gastrointest Surg       Date:  2001 Jan-Feb       Impact factor: 3.452

3.  Gastroesophageal reflux in achalasia. When is reflux really reflux?

Authors:  P F Crookes; S Corkill; T R DeMeester
Journal:  Dig Dis Sci       Date:  1997-07       Impact factor: 3.199

4.  Laparoscopic Heller cardiomyotomy and Dor fundoplication for esophageal achalasia: possible factors predicting outcome.

Authors:  G Pechlivanides; E Chrysos; E Athanasakis; J Tsiaoussis; J S Vassilakis; E Xynos
Journal:  Arch Surg       Date:  2001-11

5.  Laparoscopic treatment of functional diseases of the esophagus.

Authors:  A Peracchia; R Rosati; S Bona; U Fumagalli; L Bonavina; B Chella
Journal:  Int Surg       Date:  1995 Oct-Dec

6.  Current status of an antireflux procedure in laparoscopic Heller myotomy.

Authors:  S Lyass; D Thoman; J P Steiner; E Phillips
Journal:  Surg Endosc       Date:  2003-02-17       Impact factor: 4.584

7.  Prevalence of gastroesophageal reflux after laparoscopic Heller myotomy.

Authors:  W O Richards; R H Clements; P C Wang; C D Lind; H Mertz; J K Ladipo; M D Holzman; K W Sharp
Journal:  Surg Endosc       Date:  1999-10       Impact factor: 4.584

8.  Gastroesophageal reflux, quality of life, and satisfaction in patients with achalasia treated with open cardiomyotomy and partial fundoplication.

Authors:  Marta Ponce; Vicente Ortiz; Manuel Juan; Vicente Garrigues; Concepción Castellanos; Julio Ponce
Journal:  Am J Surg       Date:  2003-06       Impact factor: 2.565

9.  Impact of minimally invasive surgery on the treatment of esophageal achalasia: a decade of change.

Authors:  Marco G Patti; Piero M Fisichella; Silvana Perretta; Carlos Galvani; Maria V Gorodner; Thomas Robinson; Lawrence W Way
Journal:  J Am Coll Surg       Date:  2003-05       Impact factor: 6.113

10.  Objective assessment of gastroesophageal reflux after short esophagomyotomy for achalasia with the use of manometry and pH monitoring.

Authors:  J M Streitz; F H Ellis; W A Williamson; M E Glick; J A Aas; R L Tilden
Journal:  J Thorac Cardiovasc Surg       Date:  1996-01       Impact factor: 5.209

View more
  4 in total

Review 1.  Surgical treatment for achalasia: when should it be performed, and for which patients?

Authors:  Hideyuki Kashiwagi; Nobuo Omura
Journal:  Gen Thorac Cardiovasc Surg       Date:  2011-06-15

Review 2.  Current approach to the treatment of achalasia.

Authors:  Joseph G Cheatham; Roy K H Wong
Journal:  Curr Gastroenterol Rep       Date:  2011-06

3.  Laparoscopic calibrated total vs partial fundoplication following Heller myotomy for oesophageal achalasia.

Authors:  Natale Di Martino; Antonio Brillantino; Luigi Monaco; Luigi Marano; Michele Schettino; Raffaele Porfidia; Giuseppe Izzo; Angelo Cosenza
Journal:  World J Gastroenterol       Date:  2011-08-07       Impact factor: 5.742

4.  Laparoscopic Dor versus Toupet fundoplication following Heller myotomy for achalasia: results of a multicenter, prospective, randomized-controlled trial.

Authors:  Arthur Rawlings; Nathaniel J Soper; Brant Oelschlager; Lee Swanstrom; Brent D Matthews; Carlos Pellegrini; Richard A Pierce; Aurora Pryor; Valeria Martin; Margaret M Frisella; Maria Cassera; L Michael Brunt
Journal:  Surg Endosc       Date:  2011-07-26       Impact factor: 4.584

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.